Accelerate to discover
Related topics
Genotype-targeted local therapy of glioma
Mar 26, 2020
Lower-grade gliomas are often characterized by mutations in metabolism-related genes isocitrate dehydrogenase 1 (IDH1)...
Cytek spectral cytometers: 21 color panels with just 2 lasers
Mar 23, 2020
Until recently, developing multicolor fluorescence-based flow cytometry assays on a two laser system has been limited...
Cancer cells resist mechanical destruction in the circulation via RhoA-myosin II axis
Mar 20, 2020
Tumors may generate millions of Circulating tumor cells per day, but seminal work in cancer biology has established the...
IncuCyte live cell analysis system for 3D Organoids discovery
Mar 18, 2020
Live-Cell Analysis has revolutionized numerous studies, with a wide selection of applications namely 3D Tumour Spheroid...
Webinar recording: Ex vivo microangioCT, advances in microvascular imaging
Mar 16, 2020
A new technique called microangioCT imaging is being used with a novel polymerizing contrast agent that enables 3D...
Single Cell Sequencing sample preparation without centrifugation
Mar 10, 2020
Single-cell genomics is rapidly growing. Nature Methods named multimodal omics the method of the year for 2019. And as...
Comparing image quality in Phase Contrast X-Ray Tomography
Feb 28, 2020
How to evaluate and compare image quality from different submicrometer CT scans? A simple yet clever test phantom is...
Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
Feb 20, 2020
MicroPET-based dosimetry of 152Tb is feasible, and the comparison with organ harvesting resulted in acceptable dose...
Feb 12, 2019
If you are currently measuring the killing potency of an immunotherapy targeting liquid cancer cells using traditional endpoint assays such as Cr51 release and LDH assays, you are missing key elements of tumor cytotoxicity. Cancer-killing effectors do not always kill the targets at a constant pace. Have you optimized the incubation time of the effector/target co-culture and collect the readout at the peak of each cytotoxicity reaction.
We are excited to share the latest application note for xCELLigence Real Time Cell Analysis: "Evaluating Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin." The application note explains the principle of measuring the cytotoxicity of liquid tumors such as lymphoma, leukemia or myeloma continuously, in real-time and with unprecedented details. Key benefits include:
• Radiation-free
• Substantially reduced workload - just add effectors to targets and you are all set
• Continuous in real-time
• Assay windows spanning minutes to days
• Low, physiologically relevant effector:target ratios
Related technologies: Real-time, label free cell analysis
Get more info
Brand profile
ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
